Assignee
OBI PHARMA INC
TW·25 granted patents·13 pending applications·32 citations·filing 2014–2025
Top patents by PatentIndex Score
38 records- 0191US10815307B2Antibodies, pharmaceutical compositions and uses thereofOBI PHARMA INC·Filed 2017·Granted Oct 27, 2020·5 cites·9 claims
- 0290US11643456B2Human antibodies, pharmaceutical compositions and methodsOBI PHARMA INC·Filed 2017·Granted May 9, 2023·8 cites·32 claims
- 0388US11041017B2Antibodies, pharmaceutical compositions and methodsOBI PHARMA INC·Filed 2017·Granted Jun 22, 2021·4 cites·33 claims
- 0484US11000601B2Conjugated biological molecules, pharmaceutical compositions and methodsOBI PHARMA INC·Filed 2017·Granted May 11, 2021·2 cites·16 claims
- 0580US11203645B2Glycosynthase variants for glycoprotein engineering and methods of useOBI PHARMA INC·Filed 2019·Granted Dec 21, 2021·3 cites·15 claims
- 0680US10935544B2Glycan arrays and method of useOBI PHARMA INC·Filed 2016·Granted Mar 2, 2021·2 cites·29 claims
- 0779US10766914B2DNA alkylating agentsOBI PHARMA INC·Filed 2019·Granted Sep 8, 2020·1 cites·14 claims
- 0877US11642400B2Immunogenic/therapeutic glycan compositions and uses thereofOBI PHARMA INC·Filed 2017·Granted May 9, 2023·1 cites·11 claims
- 0976US10364261B2DNA alkylating agentsOBI PHARMA INC·Filed 2016·Granted Jul 30, 2019·2 cites·11 claims
- 1076US9902779B2Antibodies, pharmaceutical compositions and uses thereofOBI PHARMA INC·Filed 2015·Granted Feb 27, 2018·2 cites·11 claims
- 1172US10409869B2(R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparationOBI PHARMA INC·Filed 2016·Granted Sep 10, 2019·1 cites·20 claims
- 1271US11583577B2Cancer immunotherapy by immune activation or immune modulation via Globo series antigensOBI PHARMA INC·Filed 2017·Granted Feb 21, 2023·1 cites·31 claims
- 1369US12090212B2Conjugated biological molecules, pharmaceutical compositions and methodsOBI PHARMA INC·Filed 2020·Granted Sep 17, 2024·0 cites·8 claims
- 1466US11752204B2Vaccines with higher carbohydrate antigen density and novel saponin adjuvantOBI PHARMA INC·Filed 2019·Granted Sep 12, 2023·0 cites·5 claims
- 1565US11833223B2Antibodies, pharmaceutical compositions and methodsOBI PHARMA INC·Filed 2021·Granted Dec 5, 2023·0 cites·9 claims
- 1662US11236154B2Carbohydrate antibodies, pharmaceutical compositions and uses thereofOBI PHARMA INC·Filed 2019·Granted Feb 1, 2022·0 cites·17 claims
- 1761US11535585B2Nitrobenzyl derivatives of anti-cancer agentsOBI PHARMA INC·Filed 2020·Granted Dec 27, 2022·0 cites·19 claims
- 1859US2025276992A1Synthesis methods of acyl chain of qs-21 and derivative thereofOBI PHARMA INC·Filed 2023·Application pending·0 cites
- 1958US10501532B2Carbohydrate antibodies, pharmaceutical compositions and uses thereofOBI PHARMA INC·Filed 2016·Granted Dec 10, 2019·0 cites·4 claims
- 2056US2024084040A1Novel carbohydrate antibodies, pharmaceutical compositions and uses thereofOBI PHARMA INC·Filed 2022·Application pending·0 cites
- 2156US2024066125A1Globo series antigens-binding chimeric antigen receptors and uses thereofOBI PHARMA INC·Filed 2022·Application pending·0 cites
- 2255US12053514B2Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatmentOBI PHARMA INC·Filed 2014·Granted Aug 6, 2024·0 cites·25 claims
- 2355US10980894B2Antibodies, pharmaceutical compositions and methodsOBI PHARMA INC·Filed 2018·Granted Apr 20, 2021·0 cites·13 claims
- 2455US10517936B2Vaccines with higher carbohydrate antigen density and novel saponin adjuvantOBI PHARMA INC·Filed 2014·Granted Dec 31, 2019·0 cites·16 claims
- 2555US2025320299A1Bispecific dendritic cell engager and uses thereofOBI PHARMA INC·Filed 2025·Application pending·0 cites
- 2653US2024139301A1Active cancer immunotherapy by immune modulation via globo series antigensOBI PHARMA INC·Filed 2021·Application pending·0 cites
- 2750US11773118B2Methods of making high enantioselective secondary alcoholsOBI PHARMA INC·Filed 2020·Granted Oct 3, 2023·0 cites·20 claims
- 2850US10829437B2Nitrobenzyl derivatives of anti-cancer agentsOBI PHARMA INC·Filed 2016·Granted Nov 10, 2020·0 cites·16 claims
- 2950US2021093733A1Conjugated biological molecules, pharmaceutical compositions and methodsOBI PHARMA INC·Filed 2020·Application pending·0 cites
- 3048US2021396759A1Method for Predicting Human Immune ResponseOBI PHARMA INC·Filed 2019·Application pending·0 cites
- 3148US2020138967A1Combination therapy using anti-ssea-4 antibody in combination with therapeutic oncology agentsOBI PHARMA INC·Filed 2019·Application pending·0 cites
- 3247US12221461B2Saponin adjuvant and evaluation method thereofOBI PHARMA INC·Filed 2019·Granted Feb 11, 2025·0 cites·15 claims
- 3347US2024216401A1Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitorOBI PHARMA INC·Filed 2021·Application pending·0 cites
- 3447US2024316079A1Use of akr1c3-activated compoundOBI PHARMA INC·Filed 2021·Application pending·0 cites
- 3544US12234266B2CRM197 protein expressionOBI PHARMA INC·Filed 2019·Granted Feb 25, 2025·0 cites·5 claims
- 3642US2019389963A1Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibodyOBI PHARMA INC·Filed 2019·Application pending·0 cites
- 3740US2023181606A1Stable ast-3424 injection preparation and preparation methodOBI PHARMA INC·Filed 2020·Application pending·0 cites
- 3838US2016339089A1Immunogenic/therapeutic glycoconjugate compositions and uses thereofOBI PHARMA INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when OBI PHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →